BioSig and subsidiary ViralClear enroll patients at four sites for coronavirus trial of merimepodib

BioSig Technologies Inc (NASDAQ:BSGM) announced Monday the enrollment of patients for its Phase 2 trial of merimepodib, a drug candidate for the treatment of the coronavirus. BioSig, along with its subsidiary ViralClear Pharmaceuticals Inc, enrolled patients at trial sites in Austin, Texas; Rochester, Minnesota; Jacksonville, Florida; and Scottsdale, Arizona.  The company expects to report results later this summer. READ: BioSig Technologies set to conduct business with federal government as it applies for SAM registration "Three of our four trial sites where our partners are enrolling patients are in the recognized hot spots of Texas, Arizona, and Florida,” CEO Kenneth Londoner said in a statement. “The patients in this trial are hospitalized and requiring oxygen; therefore, providing effective treatment is of the utmost importance to all.” Merimepodib is meant to be orally administered and has demonstrated broad-spectrum in-vitro antiviral activity, including strong activity against SARS-CoV-2 in cell cultures. The study will be randomized, double blind and treat adult patients with advanced cases of the coronavirus.  BioSig, based in Connecticut, is also commercializing a proprietary biomedical processing platform designed to improve signal fidelity and uncover the full range of electrocardiogram (ECG) and intracardiac signals. Its first product, PURE EP System, is intended for acquiring, digitizing, amplifying, filtering, measuring and calculating, displaying, recording and storing of electrocardiographic and intracardiac signals for patients undergoing electrophysiology (EP) procedures in an EP laboratory. Contact Andrew Kessel at andrew.kessel@proactiveinvestors.com Follow him on Twitter @andrew_kessel